Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia Patients

BACKGROUND AND OBJECTIVES: Imatinib mesylate is approved for the treatment of Chronic Myeloid Leukemia (CML). About 20% of patients with CML do not respond to treatment with Imatinib either initially or because of acquired resistance. In addition to mutated BCR-ABL1 kinase, the organic cation transp...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Asian Pac J Cancer Prev
Hoofdauteurs: Chhikara, S, Sazawal, S, Seth, T, Chaubey, R, Singh, K, Sharma, R, Mishra, P, Mahapatra, M, Saxena, R
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: West Asia Organization for Cancer Prevention 2017
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5697457/
https://ncbi.nlm.nih.gov/pubmed/28843219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22034/APJCP.2017.18.8.2043
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items